DPP4 and obesity disorder: The SGLT2I group had a lower prevalence of obesity (4212 patients [1.9%] vs 584 patients [3.8%]), chronic kidney disease (15 408 patients [6.9%] vs 2987 patients [19.4%]), and insulin use (52 769 patients [23.5%] vs 10 036 patients [65.2%]), but had a higher prevalence of metformin (203 737 patients [90.8%] vs 11 886 patients [77.2%]) and dipeptidyl peptidase-4 inhibitor (DPP4I) (139 586 patients [62.2%] vs 11 439 patients [74.3%]) prescriptions compared with the GLP-1RAs group (absolute standardized mean difference >0.1).